ARISTADA Drug Patent Profile

When do Aristada patents expire, and what generic alternatives are available?

Aristada is a drug marketed by Alkermes Inc and is included in two NDAs. There are twenty-one patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries.

The generic ingredient in ARISTADA is aripiprazole lauroxil. There are forty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aripiprazole lauroxil profile page.

DrugPatentWatch^® Generic Entry Outlook for Aristada

Aristada was eligible for patent challenges on October 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 26, 2030. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ARISTADA

International Patents:	148
US Patents:	17
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	4
Patent Applications:	285
Drug Prices:	Drug price information for ARISTADA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARISTADA
What excipients (inactive ingredients) are in ARISTADA?	ARISTADA excipients list
DailyMed Link:	ARISTADA at DailyMed

See drug prices for ARISTADA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ARISTADA

Constraining patent/regulatory exclusivity:

8,431,576

NDA:

207533

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ARISTADA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, Los Angeles	Phase 4
Alkermes, Inc.	Phase 4
Alkermes, Inc.	Phase 3

See all ARISTADA clinical trials

Pharmacology for ARISTADA

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for ARISTADA

ARISTADA is protected by eighteen US patents.

This potential generic entry date is based on patent 8,431,576.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	ARISTADA INITIO KIT	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	209830-001	Jun 29, 2018		RX	Yes	Yes	11,154,552		Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	12,251,381
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	8,431,576			Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	11,969,469		Y

International Patents for ARISTADA

When does loss-of-exclusivity occur for ARISTADA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hong Kong

Hungary

Japan

Lithuania

New Zealand

Poland

Portugal

San Marino

Saudi Arabia

Serbia

Slovenia

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ARISTADA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	077239
Argentina	109699
Australia	2010266018
Australia	2010266040

Supplementary Protection Certificates for ARISTADA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115

ARISTADA (aripiprazole lauroxil) Market Dynamics and Financial Trajectory (Sales, Pricing, Loss of Exclusivity, and Competitive Pressures)

Last updated: July 27, 2026

ARISTADA (aripiprazole lauroxil; long-acting injectable antipsychotic) is a branded maintenance schizophrenia product in the Abbott/Alkermes commercial orbit. Its financial trajectory is driven by (1) patient demand for monthly vs every-2-month and every-3-month regimens, (2) payer contracting and utilization management in schizophrenia, (3) competitive pressure from other LAIs (including generic-adjacent channels for aripiprazole-related products depending on jurisdiction), and (4) the loss-of-exclusivity timetable for ARISTADA formulations and related patent families, which shapes generic entry risk.

---

What are ARISTADA’s key market dynamics (payer, channel, dosing schedule, and competition)?

Core demand drivers

• Long-acting injectable (LAI) conversion: ARISTADA’s commercial value concentrates in switching stable patients from oral therapy or other LAIs, and in maintaining adherence for relapse prevention.
• Dosing cadence economics: ARISTADA’s brand positioning depends on matching clinic workflows to dosing intervals (monthly and extended regimens), with payers often steering toward the lowest total cost of treatment per month of coverage.

Payer and formulary dynamics

• Broad schizophrenia formulary inclusion tends to shift over time based on net price outcomes, PBM position, and step therapy rules.
• LAIs are prone to utilization management because they carry high per-unit acquisition cost; contracting strategy and rebates determine whether ARISTADA is preferred versus competing LAIs.

Channel and reimbursement

• LAI reimbursement is sensitive to buy-and-bill dynamics, administered price frameworks, and injection-related billing. These factors can change the effective net realized price even when list prices remain stable.

Competitive set

• Direct LAI competition in schizophrenia includes other aripiprazole-based LAIs and other non-aripiprazole LAIs (paliperidone, risperidone, olanzapine, and others depending on payer preference and patient-specific tolerability).
• Competition is less about drug-to-drug equivalence and more about:
  • acquisition cost and rebate levels,
  • dosing flexibility,
  • administration convenience,
  • patient history and prior LAI response,
  • and payer-specific preferred drug lists.

---

How has ARISTADA sales performance trended over time and what drives the slope (volume vs net price)?

Sales trajectory mechanics Brand LAIs usually show:

• initial growth after launch from conversion and clinic adoption,
• mid-cycle stabilization as payer penetration matures,
• and late-cycle shifts as competition tightens and rebates adjust in response to pricing pressure.

High-signal KPIs

• Units by dosing interval: monthly vs extended interval mix is a major indicator of adherence targeting and payer steering.
• Net sales and gross-to-net delta: rebate and discount evolution is the cleanest observable proxy for payer power and channel bargaining.
• Script and treatment persistence: LAIs are adherence-driven; loss of persistence usually correlates with switching to competitors or discontinuation due to adverse events or administration burden.

What typically moves ARISTADA’s financials

• Net price pressure from:
  • new LAI entries or preferred formulary changes,
  • increased rebate intensity as payers demand lower effective cost.
• Volume sensitivity to:
  • clinic adoption of specific LAI workflows,
  • regional distributor and provider contracting,
  • and switching activity after patient stabilization or relapse.

---

When does ARISTADA lose exclusivity and how does that impact revenue risk?

Exclusivity timing framework ARISTADA’s revenue risk is shaped by two overlapping timelines:

1. regulatory exclusivity (data exclusivity and any relevant periods tied to FDA approval and new clinical investigations), and
2. patent term end for the specific ARISTADA compositions, methods of use, and/or formulation/manufacturing protections listed in the Orange Book.

Financial impact pathway

• As patent-protected exclusivity approaches end, payers and distributors begin pre-positioning, and switching to alternative LAIs accelerates.
• Generic or authorized product entry risk depends on:
  • whether ANDA filers can challenge and the likelihood of successful litigation outcomes (if relevant),
  • whether a “design-around” exists for formulation or injection device features,
  • and whether a competitor can secure formulary preference fast enough to capture prescriber momentum.

Because the exact exclusivity end dates and Orange Book last-patent-expiration dates must be sourced from the Orange Book record for each ARISTADA product code and strength, a complete, date-specific exclusivity table cannot be produced here without the underlying FDA listing data.

---

What patents protect ARISTADA and which claim types matter for generic entry?

Claim types that typically block LAI generics

• Composition-of-matter patents covering aripiprazole lauroxil formulations.
• Formulation and particle engineering claims (spray-dried dispersion characteristics, crystalline form, particle size distribution).
• Injection-related manufacturing method claims.
• Method-of-use patents tied to dosing intervals or maintenance treatment regimens.

Why claim type matters

• An ANDA for a complex long-acting injectable must match:
  • release characteristics,
  • stability under storage and handling,
  • and administration outcomes.
• Even if the active ingredient is known, formulation and manufacturing patents can be the real bottleneck.

A full patent estate map (patent numbers, assignees, filing dates, expiration dates, and claim coverage by dosage form/strength) requires Orange Book and patent-document-level data that cannot be reliably reproduced in this response without specific listings.

---

What is the Orange Book status of ARISTADA (listed patents and expiration structure by product)?

Orange Book status is product-code-specific. For ARISTADA, the practical market question is:

• which listed patents are the “blocking” patents (those with the latest expiration),
• and whether there are multiple blocks by dosage form (e.g., strength-specific listings).

A complete Orange Book table with:

• patent numbers,
• Orange Book publication/claim lists,
• expiration dates,
• and the controlling patent(s) by product code cannot be generated here without the underlying Orange Book entries.

---

Have any ANDA or Paragraph IV challenges been filed against ARISTADA?

Paragraph IV risk is a major inflection point for branded LAIs because it accelerates:

• takedown planning,
• payer recalibration,
• and settlement negotiations.

A list of any ANDA/Paragraph IV filings, the challenger identity, filing dates, and court actions must be pulled from FDA and litigation dockets and cannot be produced accurately here without those source records.

---

How does ARISTADA compare with competing long-acting injectables on market access and positioning?

Positioning variables that influence financial trajectory

• Dosing interval flexibility: longer intervals can reduce injection frequency and align with lower overhead schedules.
• Patient stability and tolerability: prior LAI response and side-effect profiles affect switching.
• Clinic and payer pathways: a preferred drug list or nonpreferred with prior authorization changes treatment selection.

Market share dynamics

• LAI market share is often “sticky” after a patient stabilizes on a regimen. That stickiness can delay immediate share loss even when competitors gain price leverage, but it can also create delayed share shifts when a payer turns over preferences or when a new product becomes the default.

A precise competitor-by-competitor comparison with quantitative market share and net sales requires external market data not provided here.

---

What commercial levers most affect ARISTADA net sales (rebates, contracting, channel inventory, and buy-and-bill)?

Rebate and discount dynamics

• PBMs commonly require higher rebate intensity when brands are not the automatic preferred option.
• LAIs experience rebasing during contracting cycles, changing net realized price even if utilization stays constant.

Administrative and logistics levers

• LAI drug handling and clinic workflow affect adherence and persistence, which then loops back into volume growth or decline.

Channel inventory

• Managed care and provider ordering patterns can affect quarterly sales timing through inventory build or draw.

---

What is ARISTADA’s financial trajectory under typical late-cycle pressures (post-peak net price compression and volume slowdown)?

Typical late-cycle outcomes

• Revenue can decline while unit volumes remain stable if net price falls faster than volume can offset.
• Net sales compression tends to precede visible volume contraction, because rebates can adjust before prescriber behavior changes.

Operational response

• Brand teams focus on:
  • retention of existing stable patients,
  • payer rescue contracting,
  • and targeted switching campaigns where medically appropriate and economically favorable.

A quantified trajectory (growth/decline rates by year, margins, and realized net price trends) needs company financial disclosures by period that are not supplied in this prompt.

---

Key Takeaways

• ARISTADA’s market performance is governed by LAI-specific demand drivers: adherence-driven persistence, dosing interval mix, payer contracting, and clinic workflow adoption.
• Financial trajectory is most sensitive to gross-to-net changes from rebates and payer positioning rather than list price alone.
• Revenue risk increases as patent and exclusivity timelines approach the end of the last blocking protections, with the practical effect showing up as payer preference shifts and faster switching once generic/authorized competition becomes feasible.
• A complete, decision-grade exclusivity and patent estate view (Orange Book blocking patents, expiration dates, and litigation/ANDA risks) requires the specific Orange Book product-code listings and litigation docket records for ARISTADA.

---

FAQs

1) What dosing intervals drive ARISTADA’s revenue performance (monthly vs every-2-month vs every-3-month)?
Dosing interval mix drives both volume and effective net price because payer acceptance and clinic scheduling influence which interval is used in maintenance therapy.

2) How do rebate and contract cycles typically affect ARISTADA net sales year over year?
Rebate intensity changes during PBM and payer renegotiations can compress net price even when unit growth slows.

3) What payer behaviors increase generic switching risk for LAI schizophrenia brands?
When a payer moves a competitor to preferred status and tightens prior authorization criteria for nonpreferred LAIs, switching accelerates for newly initiated or unstable patients first, then for stable patients over time.

4) What manufacturing or formulation factors most constrain LAI generic development for aripiprazole lauroxil?
Long-acting injectables depend on release characteristics and stability of the formulated depot system, making formulation and manufacturing method claims pivotal to generic viability.

5) How does the presence of multiple ARISTADA strengths change exclusivity and launch risk?
Orange Book listings are product-code specific; different strengths can have different controlling patents and expiration dates, shaping which strength faces earlier entry risk.

---

References

No sources were provided in the prompt, and no FDA Orange Book, patent listing, litigation docket, or company financial disclosure data was included.

DrugChatter Q&A for ARISTADA

How much does aristada cost?
Aristada hospital program?
Alkermes aristada resource?
Aristada injection used for?
Aristada alkermes resources?